Business
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding to a 63 percent growth compared to the previous year. This would generate approximately SEK 880 M in royalty to BioArctic during the same period.
About this update from Eisai Co., Ltd.
[{"type":"text","content":"STOCKHOLM, May 15, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4 billion) for their fiscal year (FY) 2026 (April 2026 through March 2027), corresponding to a 63 percent growth compared to the previous year. This would generate approximately SEK 880 M in royalty to BioArctic during the same period.","length":443,"tagName":"p"},{"type":"text","content":"Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for clinical development, marketing authorization applications and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai, and the two companies are currently preparing for a joint commercialization in the region.","length":580,"tagName":"p"},{"type":"text","content":"BioArctic's report for the first quarter 2026 will be published on May 20 at 08.00 a.m. CET.","length":96,"tagName":"p"},{"type":"text","content":"This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on May 15, 2026, at 08:30 CET.","length":259,"tagName":"p"},{"type":"text","content":"For further information, please contact: Oskar Bosson, VP Communications and Investor RelationsE-mail: [email protected]: +46 704 107 180Jenny Ljunggren, External Communications and Investor Relations ManagerE-mail: [email protected]: +46 76 013 86 08","length":302,"tagName":"p"},{"type":"text","content":"About Leqembi® (lecanemab)","length":26,"tagName":"p"},{"type":"text","content":"Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).","length":243,"tagName":"p"},{"type":"text","content":"Leqembi is approved in 53 countries an...